S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:QUREUniqure Stock Price, Forecast & News

$41.36
+0.06 (+0.15 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$40.78
Now: $41.36
$41.65
50-Day Range
$37.71
MA: $46.91
$66.78
52-Week Range
$36.20
Now: $41.36
$76.69
Volume228,358 shs
Average Volume503,798 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
Uniqure logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-240-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.28 million
Book Value$7.41 per share

Profitability

Net Income$-124,200,000.00
Net Margins-2,553.30%

Miscellaneous

Employees212
Market Cap$1.84 billion
Next Earnings Date10/26/2020 (Estimated)
OptionableOptionable
$41.36
+0.06 (+0.15 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Uniqure (NASDAQ:QURE) Frequently Asked Questions

How has Uniqure's stock been impacted by COVID-19 (Coronavirus)?

Uniqure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 13.0% and is now trading at $41.36.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Uniqure?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Uniqure
.

When is Uniqure's next earnings date?

Uniqure is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Uniqure
.

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) announced its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.31. The biotechnology company earned $1.54 million during the quarter, compared to analyst estimates of $17.87 million. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 43.95%.
View Uniqure's earnings history
.

What price target have analysts set for QURE?

13 Wall Street analysts have issued 1-year price objectives for Uniqure's stock. Their forecasts range from $56.00 to $98.00. On average, they anticipate Uniqure's share price to reach $75.75 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price.
View analysts' price targets for Uniqure
.

What are Wall Street analysts saying about Uniqure stock?

Here are some recent quotes from research analysts about Uniqure stock:
  • 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (8/4/2020)
  • 2. HC Wainwright analysts commented, "Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids." (9/3/2019)

Has Uniqure been receiving favorable news coverage?

News stories about QURE stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Uniqure earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Uniqure
.

Are investors shorting Uniqure?

Uniqure saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 5,060,000 shares, an increase of 11.2% from the December 31st total of 4,550,000 shares. Based on an average daily volume of 561,500 shares, the short-interest ratio is currently 9.0 days. Approximately 15.4% of the company's stock are sold short.
View Uniqure's Short Interest
.

Who are some of Uniqure's key competitors?

What other stocks do shareholders of Uniqure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Uniqure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Crispr Therapeutics (CRSP) and Square (SQ).

Who are Uniqure's key executives?

Uniqure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
  • Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
  • Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan, Chief Operations Officer (Age 60)

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

Who are Uniqure's major shareholders?

Uniqure's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.33%), Henry James International Management Inc. (0.28%), Phoenix Holdings Ltd. (0.26%), Swiss National Bank (0.16%), Viking Global Investors LP (0.14%) and Alps Advisors Inc. (0.13%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jack Kaye, Jeremy P Springhorn, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Robert Gut and Scott T Mcmillan.
View institutional ownership trends for Uniqure
.

Which major investors are selling Uniqure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Rhenman & Partners Asset Management AB, Alps Advisors Inc., First Trust Advisors LP, Phoenix Holdings Ltd., and Arizona State Retirement System. Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, and Robert Gut.
View insider buying and selling activity for Uniqure
.

Which major investors are buying Uniqure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Envestnet Asset Management Inc., Virtu Financial LLC, Henry James International Management Inc., Jennison Associates LLC, Lenox Wealth Management Inc., Swiss National Bank, and AE Wealth Management LLC.
View insider buying and selling activity for Uniqure
.

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $41.36.

How big of a company is Uniqure?

Uniqure has a market capitalization of $1.84 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Uniqure employs 212 workers across the globe.

What is Uniqure's official website?

The official website for Uniqure is www.uniqure.com.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.